Efficacy and safety of rituximab biosimilar in refractory lupus

AIMS: To characterise patients with refractory SLE receiving rituximab biosimilar (CT-P10) and to explore short-term efficacy and safety associated with rituximab biosimilar use. METHODS: We retrospectively analysed data from the medical records of patients with refractory SLE who received CT-P10 in...

Descripción completa

Detalles Bibliográficos
Autores principales: Pongtarakulpanit, Nantakarn, Pisitkun, Prapaporn, Ngamjanyaporn, Pintip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607610/
https://www.ncbi.nlm.nih.gov/pubmed/33139454
http://dx.doi.org/10.1136/lupus-2020-000442

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607610/
https://www.ncbi.nlm.nih.gov/pubmed/33139454
http://dx.doi.org/10.1136/lupus-2020-000442

Ejemplares similares